Total Nutraceutical Solutions Enters Into Agreement With Model Biosystems

Total Nutraceutical Solutions (TNS) has started evaluating several proprietary mushroom compounds for activity in controlling the development of Alzheimer’s Disease (AD). Model Biosystems (MBS) has informed TNS that a recent experiment in Drosophila melanogaster flies (Drosophila or fruit flies) showed that certain TNS proprietary mushrooms had unusual anti-inflammatory activity.

MBS was of the opinion that TNS should evaluate these mushroom samples in a special MBS biologic model for AD. This proprietary AD model uses a genetic mutant of Drosophila that was developed in the laboratory of Krishna Bhat, at University of Texas. This live model system can evaluate the activity of a given compound/ingredient in controlling biologic reactions and compounds that are associated with the development of human AD.

Marvin Hausman, CEO of TNS, said: “The discovery and development of organic whole foods that positively impact or help prevent diseases are welcome breakthroughs in healthcare, as more and more people demand natural alternatives to prevent disease. We believe that the unique, proprietary technology developed by TNS and used in the production of our natural organic specialty mushrooms, contributes significantly to the potential success of this new Alzheimer’s disease study to be undertaken by TNS and MBS.”